{
"id":"mk19_bb_cv_s11",
"subspecialtyId":"cv",
"title":"Atrial Fibrillation",
"jsonContent":{
"type":"section",
"id":"mk19_bb_cv_s11",
"title":{
"__html":"Atrial Fibrillation"
},
"titleNode":{
"type":"section-title",
"hlId":"5e6e34",
"children":[
"Atrial Fibrillation"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_cv_s11_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"fa5de3",
"children":[
"Findings of ",
{
"type":"abbreviation",
"title":"atrial fibrillation",
"children":[
"AF"
]
},
" include an irregularly irregular ventricular rhythm with absence of P waves in all ",
{
"type":"abbreviation",
"title":"electrocardiogram",
"children":[
"ECG"
]
},
" leads."
]
},
{
"type":"p",
"hlId":"5cc5ab",
"children":[
"Do not confuse AF with:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"c1e261",
"children":[
"sinus tachycardia with premature atrial beats"
]
},
" ",
{
"type":"list-item",
"hlId":"2c279f",
"children":[
{
"type":"abbreviation",
"title":"multifocal atrial tachycardia",
"children":[
"MAT"
]
},
" in patients with ",
{
"type":"abbreviation",
"title":"chronic obstructive pulmonary disease",
"children":[
"COPD"
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"047748",
"children":[
"Mobitz type 1 second-degree ",
{
"type":"abbreviation",
"title":"atrioventricular",
"children":[
"AV"
]
},
" block (Wenckebach) with characteristic group beating"
]
},
" ",
{
"type":"list-item",
"hlId":"f1e71f",
"children":[
"arrhythmia caused by digitalis toxicity (atrial tachycardia with block)"
]
},
" ",
{
"type":"list-item",
"hlId":"adc5ef",
"children":[
"atrial flutter with variable conduction"
]
},
" "
]
},
{
"type":"p",
"hlId":"1dd68a",
"children":[
"AF can appear as irregular, wide-complex tachycardia mimicking ",
{
"type":"abbreviation",
"title":"ventricular fibrillation",
"children":[
"VF"
]
},
" in the setting of underlying intraventricular conduction delay or in the presence of an accessory pathway."
]
},
{
"type":"p",
"hlId":"1a01ee",
"children":[
"Diagnostic studies include serum ",
{
"type":"abbreviation",
"title":"thyroid-stimulating hormone",
"children":[
"TSH"
]
},
" and digoxin level measurement (if appropriate), pulse oximetry, sleep apnea evaluation, and echocardiography."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_cv_s11_2",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"9587f9",
"children":[
"Perform emergency electrical or pharmacologic cardioversion for patients with hemodynamically unstable AF. If duration is unknown or >48 hours, institute immediate anticoagulation and continue for at least 4 weeks."
]
},
{
"type":"p",
"hlId":"b7b2a6",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Rhythm control"
]
},
" is an appropriate management for younger patients with persistent symptomatic AF and select patients with numerous cardiovascular comorbidities. Rhythm control may be achieved with medications, synchronized cardioversion, or both. If rhythm control is unsuccessful or not tolerated, catheter-based AF ablation is a more effective option."
]
},
{
"type":"p",
"hlId":"9aef53",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Rate control"
]
},
" for chronic AF or AF and normal ",
{
"type":"abbreviation",
"title":"left ventricular",
"children":[
"LV"
]
},
" function (resting ",
{
"type":"abbreviation",
"title":"hazard ratio; heart rate",
"children":[
"HR"
]
},
" <110/min) is achieved with calcium channel blockers or β-blockers."
]
},
{
"type":"p",
"hlId":"e51fec",
"children":[
"Almost all patients with AF require chronic ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"anticoagulation"
]
},
". The risk of stroke in patients who have nonvalvular AF plus one other risk factor (other than sex) exceeds the risk of hemorrhage from anticoagulation."
]
},
{
"type":"p",
"hlId":"7da90c",
"children":[
"The recommended method of assessing stroke risk in patients with nonvalvular AF is by calculating the CHA",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"DS",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-VASc score."
]
},
{
"type":"p",
"hlId":"65c670",
"children":[
"1 point each is given for:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"5d16f8",
"children":[
" ",
{
"type":"abbreviation",
"title":"heart failure",
"children":[
"HF"
]
},
" "
]
},
" ",
{
"type":"list-item",
"hlId":"c12974",
"children":[
"hypertension"
]
},
" ",
{
"type":"list-item",
"hlId":"c35b49",
"children":[
"diabetes"
]
},
" ",
{
"type":"list-item",
"hlId":"4b495f",
"children":[
"vascular disease (previous ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"myocardial infarction",
"children":[
"MI"
]
},
","
]
},
" ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"peripheral arterial disease",
"children":[
"PAD"
]
},
","
]
},
" aortic plaque)"
]
},
" ",
{
"type":"list-item",
"hlId":"0c92c8",
"children":[
"female sex"
]
},
" ",
{
"type":"list-item",
"hlId":"58e2dc",
"children":[
"age 65 to 74 years"
]
},
" "
]
},
{
"type":"p",
"hlId":"2e5845",
"children":[
"2 points each are given for:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"191e69",
"children":[
"previous stroke, ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"transient ischemic attack",
"children":[
"TIA"
]
},
","
]
},
" or thromboembolic disease"
]
},
" ",
{
"type":"list-item",
"hlId":"ede3b3",
"children":[
"age ≥75 years"
]
},
" "
]
},
{
"type":"p",
"hlId":"ce6a88",
"children":[
"Provide anticoagulation for a score ≥2 in men or ≥3 in women."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_cv_s11_inline_t1"
],
"forceOpen":true
},
{
"type":"p",
"hlId":"a0bb02",
"children":[
"In patients with AF undergoing ",
{
"type":"abbreviation",
"title":"percutaneous coronary intervention",
"children":[
"PCI"
]
},
" for ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"acute coronary syndrome",
"children":[
"ACS"
]
},
","
]
},
" anticoagulant and antiplatelet therapies are necessary. A P2Y",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" inhibitor plus an oral anticoagulant is preferred to a P2Y",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" inhibitor, oral anticoagulant, and aspirin (double therapy, not triple therapy). In patients with AF and stable ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"coronary artery disease",
"children":[
"CAD"
]
},
","
]
},
" treatment with rivaroxaban alone is noninferior to rivaroxaban plus aspirin. ",
{
"type":"alert",
"children":[
"Bridging anticoagulation is discussed in the General Internal Medicine section."
]
}
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"f9f08f",
"children":[
" ",
{
"type":"alert",
"children":[
"Only warfarin is indicated for valvular AF."
]
},
" "
]
},
" ",
{
"type":"list-item",
"hlId":"879d72",
"children":[
"Antiplatelet therapy alone is no longer routinely used for stroke prevention in AF."
]
},
" ",
{
"type":"list-item",
"hlId":"331c58",
"children":[
" ",
{
"type":"alert",
"children":[
"Do not begin calcium channel blockers, β-blockers, or digoxin in patients with AF and ",
{
"type":"abbreviation",
"title":"Wolff-Parkinson-White",
"children":[
"WPW"
]
},
" syndrome; use procainamide instead."
]
},
" "
]
},
" ",
{
"type":"list-item",
"hlId":"7a2bac",
"children":[
" ",
{
"type":"alert",
"children":[
"Adenosine is not effective for cardioversion of AF."
]
},
" "
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_cv_s11_3",
"title":{
"__html":"Test Yourself"
},
"titleNode":{
"type":"section-title",
"hlId":"7866cc",
"children":[
"Test Yourself"
]
},
"children":[
{
"type":"p",
"hlId":"889f30",
"class":"test",
"children":[
"A 55-year-old woman has dyspnea and chest pain of 12 hours' duration. ",
{
"type":"abbreviation",
"title":"blood pressure",
"children":[
"BP"
]
},
" is 75/44 mm Hg, and bibasilar crackles are heard. ECG shows a wide-complex tachycardia of 160/min."
]
},
{
"type":"p",
"hlId":"65488c",
"class":"test_answer",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Answer:"
]
},
" ",
"For management, always choose cardioversion in patients with any arrhythmia who are hemodynamically unstable."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_bb_cv_f10"
],
"forceOpen":true
}
]
}
]
},
"tablesContent":{
"mk19_bb_cv_s11_inline_t1":{
"id":"mk19_bb_cv_s11_inline_t1",
"number":1,
"bookId":"cv",
"title":{
"__html":"Study Table: Anticoagulants Approved for Stroke Prevention in Atrial Fibrillation"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"77168d",
"children":[
"Study Table: Anticoagulants Approved for Stroke Prevention in Atrial Fibrillation"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b02cd",
"class":"col hd l",
"children":[
"Type of AF"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"430286",
"class":"col hd l",
"children":[
"Cautions"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a56794",
"class":"cell txt l",
"children":[
"Warfarin (vitamin K antagonist)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab63f2",
"class":"cell txt l",
"children":[
"Nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"822c61",
"class":"cell txt l",
"children":[
"Avoid in pregnancy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8315d3",
"class":"cell txt l",
"children":[
"Dabigatran (direct thrombin inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab63f2",
"class":"cell txt l",
"children":[
"Nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f2b4c",
"class":"cell txt l",
"children":[
"Caution with P-glycoprotein inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"e5af8c",
"class":"cell txt l",
"children":[
"Reduce dose with CrCl 15-30 mL/min"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"61fdba",
"class":"cell txt l",
"children":[
"Rivaroxaban (factor Xa inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab63f2",
"class":"cell txt l",
"children":[
"Nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10bbf1",
"class":"cell txt l",
"children":[
"Avoid with CrCl <30 mL/min, moderate hepatic impairment, strong P-glycoprotein inhibitors, and strong cytochrome P-450 inducers and inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"aa214c",
"class":"cell txt l",
"children":[
"Reduce dose with CrCl 30-50 mL/min"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1cf05d",
"class":"cell txt l",
"children":[
"Apixaban (factor Xa inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab63f2",
"class":"cell txt l",
"children":[
"Nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d790b1",
"class":"cell txt l",
"children":[
"Avoid with strong P-glycoprotein inhibitors or strong cytochrome P-450 inducers and inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"0fa65e",
"class":"cell txt l",
"children":[
"Reduce dose with ≥2 of the following: creatinine ≥1.5 mg/dL, age ≥80 years, weight ≤60 kg"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d94ad",
"class":"cell txt l",
"children":[
"Edoxaban (factor Xa inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab63f2",
"class":"cell txt l",
"children":[
"Nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db600",
"class":"cell txt l",
"children":[
"Avoid with strong cytochrome P-450 inducers and inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"cb2b10",
"class":"cell txt l",
"children":[
"Avoid with CrCl >95 mL/min (reduced effectiveness in stroke prevention)"
]
},
" ",
{
"type":"p",
"hlId":"a9962b",
"class":"cell txt l",
"children":[
"Reduce dose with CrCl 30-50 mL/min, weight ≤60 kg, or concomitant use of verapamil or quinidine (potent P-glycoprotein inhibitors)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}